GlobeNewswire

Minerva Neurosciences Names Devin Smith Senior Vice President, General Counsel

Del

WALTHAM, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Devin W. Smith as Senior Vice President and General Counsel.  Mr. Smith will manage all corporate legal affairs and provide business counsel on a broad range of strategic, tactical and operational issues related to the growth of the Company and the development of its portfolio of CNS products. 

Mr. Smith was previously General Counsel and Company Secretary at Stallergenes Greer plc, a global biopharmaceutical company focused on allergy immunotherapy products.  His responsibilities encompassed support for commercial and medical activities, business development, mergers and acquisitions, corporate governance, management of claims, intellectual property, litigation and investigations, compliance and finance.  Mr. Smith joined Stallergenes from EMD Serono, Inc, the biopharmaceutical division of Merck KGaA, where he led the North American legal department as Vice President and General Counsel.  Prior to that, Mr. Smith was a partner at the international law firm of Nixon Peabody LLP, where he represented emerging and established life science, information technology and manufacturing businesses.

"Devin Smith brings a deep understanding of corporate strategic development to his position as the Company's General Counsel, and we welcome him to the Minerva management team," said Rick Russell, President of Minerva.

Mr. Smith received his law degree (cum laude) from Suffolk University Law School and a B.A. in political science from the University of North Carolina - Chapel Hill.

About Minerva Neurosciences:

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases.  Minerva's proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson's disease.  Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV."  For more information, please visit www.minervaneurosciences.com

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to Mr. Smith's positive impact on us, including as we proceed through clinical trials.  These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, Mr. Smith's and our ability to perform as expected.  These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed with the Securities and Exchange Commission on May 3, 2018.  Copies of reports filed with the SEC are posted on our website at  www.minervaneurosciences.com . The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

Contact:

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Data Privacy and Governance Solution Now Cloud-based18.6.2019 18:34:00 CESTPressemelding

HIPAAT Privacy eSuite adds support for Consent as a Service, enabling consumers to have direct control over their personal information NAPLES, FL and TORONTO, ON, June 18, 2019 (GLOBE NEWSWIRE) -- HIPAAT Inc. (HIPAAT), a leading provider of consent management, privacy-based access control and auditing solutions, today announced the release of version 6.0 of its consent engine, Privacy eSuite (PeS). The new version supports consumers’ ability to have direct control over their personal information privacy preferences. Those preferences may be recorded and managed, and – most importantly – consulted prior to their information being collected, used or disclosed. V6.0 improvements include support for HL7 Fast Health Interoperability Resources (FHIR) R4 for managing privacy policies and consent directives, RESTful interfaces for consent decisions and override requests, OAuth 2.0 protection for APIs as resources, and Open ID Connect and OAuth 2.0 for authenticating users and providing user pe

Boom Supersonic Partners with Prometheus Fuels to Supply Carbon Neutral Fuel for XB-1, its Mach-2.2 Demonstrator Aircraft18.6.2019 17:00:00 CESTPressemelding

Prometheus Fuels extracts CO2 from the air, creating hydrocarbon fuel with zero impact on greenhouse gas levels DENVER, June 18, 2019 (GLOBE NEWSWIRE) -- Boom Supersonic, the Colorado company building history’s fastest supersonic airliner, today announced a unique partnership with Prometheus Fuels. Prometheus will supply fuel during the flight test program of XB-1, Boom’s Mach-2.2 demonstrator aircraft. Boom plans to use Prometheus fuel to power XB-1 in the world’s first supersonic flight using carbon-neutral fuel. Through a process called direct air carbon capture, Prometheus removes carbon dioxide (CO2) from the air and uses clean electricity to transform it into gasoline, diesel, and jet fuel. The electricity used in this process comes from renewable sources such as solar and wind, so there are no net carbon emissions from using the fuel. “Boom is committed to making supersonic travel environmentally sustainable—we want society to enjoy the benefits of faster flight for generations

Parallels® Remote Application Server 17 Brings Simplicity and Scalability to End User Computing for Microsoft RDS, VDI and DaaS with Time-Saving Innovations18.6.2019 15:01:00 CESTPressemelding

BELLEVUE, Wash., June 18, 2019 (GLOBE NEWSWIRE) -- Today Parallels released version 17 of Parallels® Remote Application Server (Parallels RAS, parallels.com/ras) which simplifies end user computing for service providers (SPs) and enterprises. Parallels RAS 17 enables faster launch of applications by using artificial intelligence (AI), provides additional security features such as integration with Google Authenticator, and debuts a web-based helpdesk console to more easily manage Microsoft Remote Desktop Services (RDS), virtual desktop infrastructure (VDI) and desktop as a service (DaaS) infrastructure. Parallels RAS 17 is an all-in-one solution that empowers end users to consume business applications faster, reliably, and with the ability to scale within a single cloud or multiple clouds. SPs and enterprises can benefit from the Parallels RAS investment in improved management and deployment components. These provide new methods to control DaaS, VDI and Microsoft RDS, such as a new REST

Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease18.6.2019 14:29:00 CESTPressemelding

NEW YORK and CLEVELAND, June 18, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its ABO-202 program. ABO-202, the Company’s novel one-time AAV9 gene therapy for CLN1 disease, is designed to deliver a functional copy of the PPT1 gene to the central nervous system and peripheral organs using a combination of intravenous and intrathecal administrations. Abeona is preparing to initiate a Phase 1/2 clinical trial evaluating ABO-202 in patients with CLN1 disease and will provide guidance on the timing of the trial later this year. “Receiving Fast Track designation acknowledges the urgency for developing a therapy for children suffering from this rapidly-progressing and fatal disease and highlights the significant potential of ABO-202 to address this unmet need,” said João Siffert, M.D., Chief Executive Officer. ABO-202 i

Nasdaq Launches Center for Corporate Governance18.6.2019 14:00:00 CESTPressemelding

New Informational Hub to Advance Global Insights and Research on Corporate Governance and Sustainability Practices for Public, Private, and Nonprofit Organizations Publishes Inaugural Research Report on Board and Investor Priorities of S&P 100 Companies NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq: NDAQ) today announced the founding of the Nasdaq Center for Corporate Governance (the “Governance Center”), a global information and research hub that will integrate Nasdaq’s expertise, insights, and technology to accelerate the understanding of emerging corporate governance and sustainable business practices. The ambition of the Governance Center is to support the work of boards, senior executives, and governance professionals at public, private, and nonprofit organizations. “Our mission with the Governance Center is to create a resource for corporate leaders, investors, and stakeholders that includes the latest governance insights and actionable intelligence, thereby su

Inspirata Unveils Comprehensive Insight Solutions for the Cancer Care Continuum18.6.2019 13:00:00 CESTPressemelding

Leading digital pathology company now offers technology-enabled insight solutions Tampa, Florida, June 18, 2019 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology solution provider Inspirata today unveiled its new end-to-end capabilities for the cancer care continuum. Founded as a digital pathology company that pioneered the use of digital imaging for accurate cancer diagnoses, Inspirata now offers cancer registry abstraction and insight solutions to drive better cancer diagnosis, treatment, performance, and research. Inspirata’s comprehensive solutions reveal a clear picture of patients, allowing clinicians to make every moment matter in delivering cancer care. With an existing global footprint that serves over 100 institutions with automated cancer identification and reporting, and more than 30 hospitals and laboratories with digital pathology, Inspirata processes over 20 million patient reports per year, identifying all reports containing reportable cancer. Today, the comp